


## (3S,5S,6R)-Navtemadlin

<b>Cat. No.:</b>	HY-12296A		
<b>CAS No.:</b>	2459946-14-4		
<b>Molecular Formula:</b>	C <sub>28</sub> H <sub>35</sub> Cl <sub>2</sub> NO <sub>5</sub> S		
<b>Molecular Weight:</b>	568.55		
<b>Target:</b>	Others		
<b>Pathway:</b>	Others		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (175.89 mM)  
 \* "≥" means soluble, but saturation unknown.

Concentration	Mass		
	1 mg	5 mg	10 mg
<b>1 mM</b>	1.7589 mL	8.7943 mL	17.5886 mL
<b>5 mM</b>	0.3518 mL	1.7589 mL	3.5177 mL
<b>10 mM</b>	0.1759 mL	0.8794 mL	1.7589 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

(3S,5S,6R)-Navtemadlin is the isomer of Navtemadlin (HY-12296), and can be used as an experimental control. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC<sub>50</sub> of 0.6 nM. Navtemadlin binds to MDM2 with a K<sub>d</sub> of 0.045 nM<sup>[1][2]</sup>.

### REFERENCES

[1]. Canon J, et al. The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents. Mol Cancer Ther. 2015 Mar;14(3):649-58.

[2]. Rew Y, et al. Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer. J Med Chem. 2014 Aug 14;57(15):6332-41.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA